Silver nanoparticles (AgNPs) in the control of Staphylococcus spp

Area of Science:

• Microbiology
• Nanotechnology
• Infectious Diseases

Background:

• Staphylococcus bacteria, particularly Staphylococcus aureus, are significant causes of infections.
• Coagulase-negative Staphylococcus (CoNS) are major nosocomial pathogens linked to biofilm formation on medical devices.
• Methicillin-resistant Staphylococcus aureus (MRSA) and multidrug-resistant (MDR) CoNS present treatment challenges in hospital environments.

Purpose of the Study:

• To investigate the potential of nanoparticles (NPs), specifically silver nanoparticles (AgNPs), as an alternative strategy for controlling Staphylococcus infections.
• To evaluate the efficacy of AgNPs against both Staphylococcus aureus and coagulase-negative Staphylococcus (CoNS), with a focus on in vivo applications.

Main Methods:

• Review of in vitro studies evaluating AgNPs against Staphylococcus aureus and MRSA.
• Analysis of in vivo studies exploring the application of AgNPs against CoNS on skin models.

Main Results:

• In vitro studies confirm the broad-spectrum antibacterial activity of AgNPs against Staphylococcus aureus and MRSA.
• In vivo research demonstrates the effectiveness of AgNPs in controlling CoNS on skin, elucidating their biological activity.
• AgNPs exhibit low toxicity and can be used in combination with other treatments.

Conclusions:

• Nanoparticles, especially AgNPs, represent a viable alternative for managing Staphylococcus and multidrug-resistant CoNS skin infections.
• AgNP application can prevent the worsening of clinical conditions and promote tissue regeneration in infected areas.